Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | RECQL | P46063 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | POLM | Q9NP87 | 2/20 | 0.60 |
| ▸ | POLK | Q9UBT6 | 2/20 | 0.60 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.60 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.60 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.52 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | F7 | P08709 | 3/20 | 0.48 |
| ▸ | F3 | P13726 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17369039 | 1.00 | KDM4E (0.75) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL454163 | 1.00 | KDM4E (0.75) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL16800411 | 0.97 | KDM4E (0.71) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL17369041 | 0.97 | KDM4E (0.71) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL8439129 | 0.96 | KDM4E (0.73) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL469664 | 0.96 | KDM4E (0.73) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL16770314 | 0.95 | KDM4E (0.71) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL17369042 | 0.95 | KDM4E (0.71) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL16800484 | 0.95 | KDM4E (0.71) | KDM4ERECQLMEN1KMT2APOLM | |
| SCHEMBL8814964 | 0.94 | KDM4E (0.73) | KDM4ERECQLMEN1KMT2APOLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271356-A1 | COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022118982-A1 | PROCESS FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022118978-A1 | COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022118980-A1 | COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2022-06-09 | — | — | WO | disclosed |
| US-20150374839-A1 | NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES | KEAN UNIVERSITY (US) | 2015-12-31 | — | — | US | disclosed |
| US-9056139-B2 | Fatty acid-salicylate conjugates with enhanced therapeutic properties | KEAN UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| CN-102655839-B | A cosmetic or dermatological composition with low stickiness, containing a lipophilic active ingredient | OREAL | 2014-11-12 | — | — | CN | disclosed |
| CN-102655839-A | A cosmetic or dermatological composition with low stickiness, containing a lipophilic active ingredient | OREAL | 2012-09-05 | — | — | CN | disclosed |
| WO-2012093103-A2 | TWO-PART COSMETIC PRODUCT | L'OREAL (FR) | 2012-07-12 | — | — | WO | disclosed |
| CN-101744739-A | Use of an ester derived from 4-carboxy-2-pyrrolidinone as a solvent in cosmetic compositions and cosmetic compositions containing the ester | OREAL | 2010-06-23 | — | — | CN | disclosed |
| US-6368615-B1 | POLYMER OF UNSATURATED ESTER OF SALICYLIC ACID | GUTTAG ALVIN (US) | 2002-04-09 | — | — | US | disclosed |
| US-6037338-A | AND REDUCING RISK OF HEART ATTACKS | GUTTAG ALVIN (US) | 2000-03-14 | — | — | US | disclosed |
| US-5910511-A | ALTERNATIVE TO ASPIRIN WHICH HAS LESSER UNDESIRABLE SIDE EFFECTS | GUTTAG ALVIN (US) | 1999-06-08 | — | — | US | disclosed |
| US-5760261-A | ANTINFLAMMATORY AGENTS, ANTIPYRETICS, ANALGESICS; SIDE EFFECTREDUCTION | GUTTAG ALVIN (US) | 1998-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374839-A1 | NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES | FASN, ELOVL1, ELOVL3 | KDM4E 2152/4885RECQL 3422/4885MEN1 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.